Does anyone know Galderma?

In the first half of 2026, 13 leading global aesthetic medicine listed companies headquartered in Europe, the U.S., and South Korea delivered financial results marked by a significantly widening growth divergence. The European contingent—represented by Galderma and Ipsen—outperformed their American and Korean peers, achieving above-expectation growth thanks to deep product portfolios and globalized operations. Galderma’s net sales for the first half of 2026 surpassed $3 billion for the first time, reaching $3.134 billion—a 24.6% year-on-year increase—and far exceeding market consensus. Its profit totaled $802 million, cementing its status as the undisputed global leader in aesthetic medicine. Then, among China’s many leading aesthetic medicine enterprises, which one could be dubbed “China’s Galderma”? This article analyzes Galderma’s business structure, financial characteristics, and competitive moats to identify the Chinese aesthetic medicine company most likely to evolve into “Galderma.” I. Galderma’s Archetype: What Defines a “Dermatology Science Company”? To answer this question, we must precisely deconstruct Galderma’s business model—not merely label it a “global aesthetic medicine leader.” 1.1 Business Structure: Synergistic Logic Across Three Pillars Galderma’s core strategy is “Integrated Dermatology,” spanning three business pillars: The synergistic value across these three pillars lies in: dermatological therapeutics establishing professional trust with dermatologists; injectable aesthetics converting that trust into high-margin consumer spending; and daily skincare extending engagement beyond clinical settings to enable full-lifecycle user management. This funnel model—“medical expertise → consumer conversion → routine repurchase”—is Galderma’s fundamental moat, distinguishing it from pure aesthetic medicine firms or pure skincare companies. 1.2 The Essence of Competitive Moats Galderma’s moat is not rooted in any single product, but rather in the brand portfolio and channel synergy underpinned by its foundational narrative of “dermatology science.” Its origins as the skin health division of Nestlé endowed it with deep pharmaceutical R&D DNA; meanwhile, Cetaphil’s decades-long presence in mass-market skincare has provided Galderma’s aesthetic business with a vast consumer entry point. This cross-domain capability—from pharmaceuticals to aesthetics—is currently missing across most Chinese aesthetic medicine enterprises. 1.3 Financial Characteristics and Growth Quality In the first half of 2026, Galderma’s dermatological therapeutics segment surged nearly 68% year-on-year, while injectable aesthetics maintained steady growth and daily skincare posted positive growth despite weak overall consumer demand. Its core EBITDA margin stood at approximately 22.7%, sustaining profitability quality even amid scale expansion. The company operates in around 90 countries and regions, went public on the SIX Swiss Exchange in March 2024, and currently boasts a market capitalization of roughly CHF 36.85 billion (approximately RMB 34 billion). II. Benchmarking Analysis: Screening Chinese Enterprises Across Five Dimensions of Galderma Using Galderma’s five core attributes as benchmarks, we systematically evaluate major Chinese aesthetic medicine enterprises: Dimension One: Completeness of Product Portfolio (Injectables + Skincare + Therapeutics)

Blackstone is preparing an exit: RMB 13.4 billion!

In October 2020, Blackstone acquired a majority stake in ZO Skin Health through its Tactical Opportunities (“Tac Opps”) fund and has held it for six years. After Blackstone’s acquisition, Dr. Zein Obagi—the founder—remained on board as Medical Director of the brand and did not fully step away. Should a new buyer take over, it remains unclear whether Dr. Obagi’s role would change. Dr. Obagi is a serial entrepreneur. In 1988, he founded Obagi Medical and launched the iconic Nu-Derm skin-renewal system. Later, however, he departed the company. After leaving Obagi Medical, Dr. Obagi officially founded ZO Skin Health in 2007, embedding his next-generation philosophy of skin health into this new brand. Because both brands share the same founder, many people mistakenly conflate ZO Skin Health with Obagi Medical—but they are in fact two independent, unaffiliated companies. Dr. Obagi is a world-renowned authority in chemical peels and pigmentary skin disorders, and author of the professional monograph *The Art of Skin Health Restoration and Rejuvenation*. His core philosophy—that skincare should aim not merely to improve superficial symptoms but to restore the overall health of skin tissue—fully informs the development logic of ZO’s entire product line.

Galderma agrees to buy ZO Skin Health for around $1.5 billion, sources say

22 hours ago

Swiss skincare conglomerate Galderma agreed to acquire medical-grade skincare firm ZO Skin Health for approximately $1.5 billion, expanding its US market presence alongside key brands like Cetaphil and Dysport.

Galderma to buy US firm ZO Skin Health for $1.5 billion

reuters

reuters

2026-10-13

Galderma agrees to buy ZO Skin Health for around $1.5 billion, sources say

Galderma agrees to buy ZO Skin Health for around $1.5 billion, sources say

FAQ